VolitionRx (NYSE:VNRX) Coverage Initiated by Analysts at StockNews.com

StockNews.com started coverage on shares of VolitionRx (NYSE:VNRX) in a report issued on Monday morning. The brokerage issued a sell rating on the stock.

Separately, Benchmark reaffirmed a “hold” rating on shares of VolitionRx in a research note on Friday, August 16th.

VolitionRx Stock Performance

NYSE VNRX opened at $0.66 on Monday. The company has a market capitalization of $60.59 million, a P/E ratio of -1.64 and a beta of 1.10. VolitionRx has a 52-week low of $0.43 and a 52-week high of $1.23. The company has a fifty day moving average of $0.68 and a 200-day moving average of $0.69.

VolitionRx (NYSE:VNRX) last issued its quarterly earnings results on Wednesday, August 14th. The company reported ($0.08) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.09) by $0.01. The firm had revenue of $0.40 million for the quarter, compared to the consensus estimate of $0.34 million. As a group, analysts forecast that VolitionRx will post -0.31 EPS for the current fiscal year.

Insider Buying and Selling at VolitionRx

In other VolitionRx news, Director Guy Archibald Innes acquired 150,000 shares of the business’s stock in a transaction dated Tuesday, August 20th. The shares were purchased at an average cost of $0.67 per share, for a total transaction of $100,500.00. Following the transaction, the director now owns 406,683 shares in the company, valued at $272,477.61. This represents a 0.00 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 12.80% of the stock is currently owned by corporate insiders.

Institutional Trading of VolitionRx

A hedge fund recently raised its stake in VolitionRx stock. Ground Swell Capital LLC grew its holdings in shares of VolitionRx Limited (NYSE:VNRX) by 78.8% in the 3rd quarter, according to its most recent disclosure with the SEC. The fund owned 45,959 shares of the company’s stock after purchasing an additional 20,249 shares during the period. Ground Swell Capital LLC’s holdings in VolitionRx were worth $28,000 as of its most recent SEC filing. 8.09% of the stock is currently owned by institutional investors and hedge funds.

About VolitionRx

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes.